PMID- 30192820
OWN - NLM
STAT- MEDLINE
DCOM- 20190225
LR  - 20190225
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 9
DP  - 2018
TI  - The prevalence of antibodies against the HLA-DRB3 protein in kidney 
      transplantation and the correlation with HLA expression.
PG  - e0203381
LID - 10.1371/journal.pone.0203381 [doi]
LID - e0203381
AB  - Human leukocyte antigen (HLA)-DRB3 is a functional HLA class II gene, which has a 
      limited allele diversity in the human population. Furthermore, the HLA-DRB3 gene 
      is only present in a subset of individuals. Therefore, in organ transplantation, 
      this HLA molecule is frequently mismatched between patient and graft donor and 
      thus antibodies against this mismatched HLA molecule can develop. In this study, 
      we aimed to evaluate the prevalence and reactivity of these antibodies and aimed 
      to identify factors that underlie antibody formation against HLA-DRB3. We showed 
      in our patient cohort that HLA-DRB3 antibodies are identified in about 7% of all 
      patients that were screened with solid phase assays. In these assays, we observed 
      multiple antibody reactivity patterns indicating that HLA-DRB3 harbours multiple 
      epitopes. In those cases, where we succeeded at tracing back the induction of 
      these antibodies to the molecular HLA typing of the immunogenic event, we noticed 
      a different frequency of HLA-DRB1 allele groups in the donors as compared to a 
      control group. To a certain extent this distribution (e.g. HLA-DRB1*11 
      individuals) could be linked to an altered expression level. However, it also 
      appears that different HLA-DRB3 alleles (e.g. HLA-DRB3*01 group) vary in their 
      immunogenicity without having an expression difference. In conclusion, our study 
      provides information on the immunogenicity and reactivity patterns of antibodies 
      against HLA-DRB3 in kidney transplantation, and it points towards the possibility 
      of HLA expression as a factor underlying antibody formation.
FAU - Habets, Thomas H P M
AU  - Habets THPM
AUID- ORCID: 0000-0003-0393-3394
AD  - Department of Transplantation Immunology, Tissue Typing Laboratory, Maastricht 
      University Medical Center +, Maastricht, The Netherlands.
AD  - Department of Internal Medicine, Division of Hematology, Maastricht University 
      Medical Center +, Maastricht, The Netherlands.
FAU - Hepkema, Bouke G
AU  - Hepkema BG
AD  - Transplantation Immunology, Department of Laboratory Medicine, University of 
      Groningen, University Medical Center Groningen, Groningen, The Netherlands.
FAU - Kouprie, Niels
AU  - Kouprie N
AD  - Transplantation Immunology, Department of Laboratory Medicine, University of 
      Groningen, University Medical Center Groningen, Groningen, The Netherlands.
FAU - Schnijderberg, Melanie C A
AU  - Schnijderberg MCA
AD  - Department of Internal Medicine, Division of Hematology, Maastricht University 
      Medical Center +, Maastricht, The Netherlands.
FAU - van Smaalen, Tim C
AU  - van Smaalen TC
AD  - Department of Surgery, Maastricht University Medical Center +, Maastricht, The 
      Netherlands.
FAU - Bungener, Laura B
AU  - Bungener LB
AD  - Transplantation Immunology, Department of Laboratory Medicine, University of 
      Groningen, University Medical Center Groningen, Groningen, The Netherlands.
FAU - Christiaans, Maarten H L
AU  - Christiaans MHL
AD  - Department of Internal Medicine, Division of Nephrology, Maastricht University 
      Medical Center +, Maastricht, The Netherlands.
FAU - Bos, Gerard M J
AU  - Bos GMJ
AD  - Department of Internal Medicine, Division of Hematology, Maastricht University 
      Medical Center +, Maastricht, The Netherlands.
AD  - CiMaas BV, Maastricht, The Netherlands.
FAU - Vanderlocht, Joris
AU  - Vanderlocht J
AD  - Department of Transplantation Immunology, Tissue Typing Laboratory, Maastricht 
      University Medical Center +, Maastricht, The Netherlands.
AD  - Department of Internal Medicine, Division of Hematology, Maastricht University 
      Medical Center +, Maastricht, The Netherlands.
AD  - Central Diagnostic Laboratory, Maastricht University Medical Center +, 
      Maastricht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20180907
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antibodies)
RN  - 0 (Epitopes)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB3 Chains)
SB  - IM
MH  - Alleles
MH  - Antibodies/*blood/immunology
MH  - Epitopes/genetics/metabolism
MH  - Gene Frequency
MH  - Graft Survival
MH  - HLA Antigens/*genetics/metabolism
MH  - HLA-DRB1 Chains/genetics/metabolism
MH  - HLA-DRB3 Chains/*genetics/immunology/metabolism
MH  - Histocompatibility Testing/methods
MH  - Humans
MH  - *Kidney Transplantation
MH  - Tissue Donors
PMC - PMC6128541
COIS- Gerard M.J. Bos is CEO of CiMaas BV, Maastricht, a start-up/spin-off company of 
      Maastricht University. There are no patents, products in development or marketed 
      products to declare. This does not alter our adherence to all the PLOS ONE 
      policies on sharing data and materials, as detailed online in the guide for 
      authors.
EDAT- 2018/09/08 06:00
MHDA- 2019/02/26 06:00
PMCR- 2018/09/07
CRDT- 2018/09/08 06:00
PHST- 2018/01/14 00:00 [received]
PHST- 2018/08/20 00:00 [accepted]
PHST- 2018/09/08 06:00 [entrez]
PHST- 2018/09/08 06:00 [pubmed]
PHST- 2019/02/26 06:00 [medline]
PHST- 2018/09/07 00:00 [pmc-release]
AID - PONE-D-17-45308 [pii]
AID - 10.1371/journal.pone.0203381 [doi]
PST - epublish
SO  - PLoS One. 2018 Sep 7;13(9):e0203381. doi: 10.1371/journal.pone.0203381. 
      eCollection 2018.